Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Importance: Immune checkpoint inhibitors (ICI) have revolutionized the treatment for gastroesophageal cancers (GEC). It is important to investigate the factors that influence the response to anti-PD-1/PD-L1 ICIs. Objective: To assess the benefits of PD-1/PD-L1 ICIs in advanced GEC and perform subgro...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Kanak, Subramanyam, Sai, Attwood, Kristopher, Appiah, Duke, Fountzilas, Christos, Mukherjee, Sarbajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501109/
https://www.ncbi.nlm.nih.gov/pubmed/36145703
http://dx.doi.org/10.3390/pharmaceutics14091953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501109/
https://www.ncbi.nlm.nih.gov/pubmed/36145703
http://dx.doi.org/10.3390/pharmaceutics14091953

Ejemplares similares